Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting

References

• Coates A, Abraham S, Kaye SB et al. On the receiving end – patient perception of the side-effects of cancer chemotherapy. Eur. J. Cancer Clin. Oncol.19, 203–208 (1983).
   PubMedGoogle Scholar
• Griffin AM, Butow PN, Coates AS et al. On the receiving end V: patients perceptions of the side-effects of cancer chemotherapy in 1993. Ann. Oncol.7, 189–195 (1996).
   PubMed Web of Science ®Google Scholar
• Gralla RJ, Itri LM, Pisko SE et al. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N. Engl. J. Med.305, 905–909 (1981).
   PubMed Web of Science ®Google Scholar
• Miner WD, Sanger GJ. Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br. J. Pharmac.88, 497–499 (1986).
   PubMed Web of Science ®Google Scholar
• Cunningham D, Hawthorn J, Pople A et al. Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist. Lancet1(8548), 1461–1463 (1987).
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Murphy WK, Lester EP et al. GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis. J. Clin. Oncol.7(6), 700–705 (1989).
   PubMed Web of Science ®Google Scholar
• Marty M, Pouillart P, Scholl S et al. Comparison of the 5-hydroxytryptamine 3 (serotonin) antagonist (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N. Engl. J. Med.322, 816–821 (1990).
   PubMed Web of Science ®Google Scholar
• Italian Group for Antiemetic Research. Ondansetron + dexamethasone vs. metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Lancet340, 96–99 (1992).
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Grunberg SM, Gralla RJ et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin – the aprepitant protocol 052 study group. J. Clin. Oncol.21, 4112–4119 (2003).
   PubMed Web of Science ®Google Scholar
• Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al. Addition of the Neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Cancer97, 3090–3098 (2003).
   PubMed Web of Science ®Google Scholar
• Warr DG, Hesketh PJ, Gralla RJ et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J. Clin. Oncol.23, 2822–2830 (2005).
   PubMed Web of Science ®Google Scholar
• Schmoll HJ, Aapro MS, Poli-Bigelli S et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann. Oncol.17, 1000–1006 (2006).
   PubMed Web of Science ®Google Scholar
• Herrstedt J, Apornwirat W, Shaharyar A et al. Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. J. Clin. Oncol.27, 5363–5369 (2009).
   PubMed Web of Science ®Google Scholar
• Grunberg SM, Rolski J, Strausz J et al. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial. Lancet Oncol.10, 549–558 (2009).
   PubMed Web of Science ®Google Scholar
• Rapport MM, Green AA, Page IH. Partial purification of the vasoconstrictor in beef serum. J. Biol. Chem.174, 735–741 (1948).
   Google Scholar
• Rapport MM. Serum vasoconstrictor (serotonin). V. The presence of creatinine in the complex. A proposed structure of the vasoconstrictor principle. J. Biol. Chem.180, 961–969 (1949).
   PubMed Web of Science ®Google Scholar
• Gaddum JH. Tryptamine receptors. J. Physiol.119, 363–368 (1952).
   Google Scholar
• Gaddum JH, Picarelli ZP. Two kinds of tryptamine receptor. Br. J. Pharmacol.12, 323–328 (1957).
   PubMed Web of Science ®Google Scholar
• Baez M, Kursar JD, Helton LA, Wainscott DB, Nelson DL. Molecular biology of serotonin receptors. Obes. Res.3(Suppl. 4), 441S–447S (1995).
   Google Scholar
• Wong EHF, Clark R, Leung E et al. The interaction of RS 25259–25197, a potent and selective antagonist, with 5-HT3 receptors, in vitro. Br. J. Pharmacol.114, 851–859 (1995).
   PubMed Web of Science ®Google Scholar
• Rojas C, Stathis M, Thomas AG et al. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth. Analg.107(2), 469–478 (2008).
   PubMed Web of Science ®Google Scholar
• Rojas C, Thomas AG, Alt J et al. Palonosetron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor function. Eur. J. Pharmacol.626(2–3), 193–199 (2010).
   PubMed Web of Science ®Google Scholar
• Eglen RM, Lee CH, Smith WL et al. Pharmacological characterization of RS 25259–25197, a novel and selective 5-HT3 receptor antagonist, in vivo. Br. J. Pharmacol.114, 860–866 (1995).
   PubMed Web of Science ®Google Scholar
• Trissel LA, Xu QA. Physical and chemical stability of palonosetron HCl in 4 infusion solutions. Ann. Pharmacother.38, 1608–1611 (2004).
   Google Scholar
• Trissel LA, Zhang YP. Physical and chemical stability of palonosetron HCl with cisplatin, carboplatin, and oxaliplatin during simulated Y-site administration. J. Oncol. Pharm. Pract.10, 191–195 (2004).
   Google Scholar
• Trissel LA, Zhang Y. Palonosetron HCl compatibility and stability with doxorubicin HCl and epirubicin HCl during simulated Y-site administration. Ann. Pharmacother.39, 280–283 (2005).
   Google Scholar
• Trissel LA, Xu QA. Physical and chemical stability of palonosetron HCl with topotecan HCl and irinotecan HCl during simulated Y-site administration. Int. J. Pharm. Compound9, 238–241 (2005).
   Google Scholar
• Trissel LA, Xu QA. Physical and chemical compatibility of palonosetron HCl with lorazepam and midazolam HCl during simulated Y-site administration. Int. J. Pharm. Compound9, 235–237 (2005).
   Google Scholar
• Trissel LA, Zhang Y. Physical and chemical stability of palonosetron hydrochloride with fluorouracil and with gemcitabine hydrochloride during simulated Y-site administration. Int. J. Pharm. Compound.9, 320–322 (2005).
   Google Scholar
• Xu QA, Trissel LA. Physical and chemical stability of palonosetron hydrochloride with cyclophosphamide and ifosfamide during simulated Y-site administration. Am. J. Health Syst. Pharm.62, 1998–2000 (2005).
   Google Scholar
• Trissel LA, Zhang Y, Xu QA. Physical and chemical stability of palonosetron HCl with dacarbazine and methylprednisolone sodium succinate during simulated Y-site administration. Int. J. Pharm. Compound10, 234–236 (2006).
   Google Scholar
• Trissel LA, Zhang Y. Compability and stability of Aloxi (palonosetron hydrochloride) admixed with dexamethasone sodium phosphate. Int. J. Pharm. Compound10, 398–403 (2004).
   Google Scholar
• Xu QA, Trissel LA. Stability of palonosetron hydrochloride with paclitaxel and docetaxel during simulated Y-site administration. Am. J. Health Syst. Pharm.61, 1596–1598 (2004).
   Google Scholar
• Trissel LA, Trusley C, Ben M et al. Physical and chemical stability of palonosetron hydrochloride with five opiate agonists during simulated Y-site administration. Am. J. Health Syst. Pharm.64, 1209–1213 (2007).
   Google Scholar
• Trusley C, Ben M, Kupiec TC et al. Palonosetron physical and chemical stability with metoclopramide and promethazine during simulated Y-site administration. Int. J. Pharm. Compound.11, 82–85 (2007).
   Google Scholar
• Stoltz R, Cyong JC, Shah A, Parisi S. Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects. J. Clin. Pharmacol.44, 520–531 (2004).
   PubMed Web of Science ®Google Scholar
• Stoltz R, Parisi S, Shah A, Macciocchi A. Pharmacokinetics, metabolism and excretion of intravenous [l4C]-palonosetron in healthy human volunteers. Biopharm. Drug Dispos.25, 329–337 (2004).
   PubMed Web of Science ®Google Scholar
• Hunt TL, Gallagher SC, Cullen MT, Shah AK. Evaluation of safety and pharmacokinetics of consecutive multiple-day dosing of palonosetron in healthy subjects. J. Clin. Pharmacol.45, 589–596 (2005).
   PubMed Web of Science ®Google Scholar
• Gralla R, Lichinitser M, Van der Vegt S et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized Phase III trial comparing single doses of palonosetron with ondansetron. Ann. Oncol.14, 1570–1577 (2003).
   PubMed Web of Science ®Google Scholar
• Eisenberg P, Figueroa-Vadillo J, Zamora R et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist. Results of a Phase III, single-dose trial versus dolasetron. Cancer98(11), 2473–2482 (2003).
   PubMed Web of Science ®Google Scholar
• Aapro MS, Grunberg SM, Manikhas GM et al. A Phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann. Oncol.17, 1441–1449 (2006).
   PubMed Web of Science ®Google Scholar
• Saito M, Aogi K, Sekine I et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative Phase III trial. Lancet Oncol.10, 115–124 (2009).
   PubMed Web of Science ®Google Scholar
• Shah AK, Hunt TL, Gallagher SC, Cullen MT. Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. Curr. Med. Res. Opin.21(4), 595–601 (2005).
   PubMed Web of Science ®Google Scholar
• Eisenberg P, MacKintosh FR, Ritch P, Cornett PA, Macciocchi A. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Ann. Oncol.15, 330–337 (2004).
   PubMed Web of Science ®Google Scholar
• Grote T, Hajdenberg J, Cartmell A, Ferguson S, Ginkel A, Charu V. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. J. Support. Oncol.4, 403–408 (2006).
   PubMedGoogle Scholar
• Hajdenberg J, Grote T, Yee L, Arevalo-Araujo R, Latimer LA. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting. J. Support. Oncol.4, 467–471 (2006).
   PubMedGoogle Scholar
• Navari RM, Einhorn LH, Loehrer PJ et al. A Phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study. Support. Care Cancer15, 1285–1291 (2007).
   PubMed Web of Science ®Google Scholar
• Einhorn LH, Brames MJ, Dreicer R, Nichols CR, Cullen MT, Bubalo J. Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support. Care Cancer15, 1293–1300 (2007).
   PubMed Web of Science ®Google Scholar
• Musso M, Scalone R, Bonanno V et al. Palonosetron (Aloxi®) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy. Support. Care Cancer17, 205–209 (2009).
   PubMed Web of Science ®Google Scholar
• Petru E, Andel J, Angleitner-Boubenizek L et al. Early Austrian multicenter experience with palonosetron as antiemetic treatment for patients undergoing highly or moderately emetogenic chemotherapy. Wien. Med. Wochenschr.158(5–6), 169–173 (2008).
   Google Scholar
• Herrington JD, Jaskiewicz AD, Song J. Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer112(9), 2080–2087 (2008).
   PubMed Web of Science ®Google Scholar
• Sepúlveda-Vildósola AC, Betanzos-Cabrera Y, Lastiri GG et al. Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children. Arch. Med. Res.39(6), 601–606 (2008).
   PubMed Web of Science ®Google Scholar
• Yu Z, Liu W, Wang L et al. The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a Phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial. Support. Care Cancer17, 99–102 (2009).
   PubMed Web of Science ®Google Scholar
• Musso M, Scalone R, Crescimanno A et al. Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT. Bone Marrow Transplant.45, 123–127 (2009).
   Google Scholar
• Massa E, Astara G, Madeddu C et al. Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response. Crit. Rev. Oncol. Hematol.70(1), 83–91 (2009).
   PubMedGoogle Scholar
• Grunberg SM, Dugan M, Muss H et al. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. Support. Care Cancer17, 589–594 (2009).
   PubMed Web of Science ®Google Scholar
• Lorusso V, Spedicato A, Petrucelli L, Saracino V, Giampaglia M, Perrone T. Single dose of palonosetron plus dexamethasone to control nausea, vomiting and to warrant an adequate food intake in patients treated with highly emetogenic chemotherapy (HEC). Preliminary results. Support. Care Cancer17(12), 1469–1473 (2009).
   Google Scholar
• Maemondo M, Masuda N, Sekine I et al. A Phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy. Ann. Oncol.20(11), 1860–1866 (2009).
   PubMed Web of Science ®Google Scholar
• Segawa Y, Aogi K, Inoue K et al. A Phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy. Ann. Oncol.20(11), 1874–1880 (2009).
   PubMed Web of Science ®Google Scholar
• Raftopoulos H, Bria E, Gralla R, Lesser M, Napolitano B, Giannarelli D. Is there a preferred dose of palonosetron? Results of an abstracted data (AD) meta-analysis (MA) of all eight randomized double-blind (RDB) studies and the impact on guideline considerations. J. Clin. Oncol.27(15S), (2009) (Abstract 9636).
   Google Scholar